Affymax, a biopharmaceutical company, has appointed Karin Walker, certified public accountant (CPA), as vice president of finance and chief accounting officer (CAO). Walker has over two decades of financial management experience, including in the biotechnology and pharmaceutical industries. In this newly created position she will report to Herb Cross, chief financial officer (CFO), and will be responsible for the strategic and operational leadership of the finance function and accounting activities.
Prior to joining Affymax, Walker served as vice president of finance and corporate controller at Amyris, overseeing all accounting functions during the biotechnology company’s transition from a development-stage company to a commercial organisation. Before joining Amyris in 2009, she was vice president of finance and corporate controller for CV Therapeutics, a biopharmaceutical company, where she built a robust finance function to support corporate growth and a number of complex transactions and strategic initiatives.
Walker has also served in senior financial leadership roles at companies such as Knight Ridder Digital, Accellion and Niku. She earned a BS degree in business from the California State Polytechnic University, San Luis Obispo.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.